Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $21.28, but opened at $20.74. Genmab A/S shares last traded at $21.07, with a volume of 161,378 shares trading hands.

Wall Street Analysts Forecast Growth

GMAB has been the topic of several recent analyst reports. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Stock Down 1.5%

The stock has a market cap of $13.44 billion, a price-to-earnings ratio of 12.04, a PEG ratio of 2.65 and a beta of 1.04. The stock's fifty day moving average is $19.81 and its 200-day moving average is $20.66.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. As a group, equities research analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently made changes to their positions in the business. Marotta Asset Management lifted its position in shares of Genmab A/S by 5.8% in the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after purchasing an additional 739 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock valued at $186,000 after acquiring an additional 827 shares in the last quarter. Gallacher Capital Management LLC lifted its holdings in shares of Genmab A/S by 6.8% in the first quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock worth $281,000 after acquiring an additional 915 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Finally, Lindbrook Capital LLC raised its holdings in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after buying an additional 950 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.